Dawidczyk, Charlene M. Kim, Chloe Park, Jea Ho Russell, Luisa M. Lee, Kwan Hyi Pomper, Martin G. Searson, Peter C. 2024-01-20T09:03:43Z 2024-01-20T09:03:43Z 2021-09-02 2014-08-10 0168-3659 https://pubs.kist.re.kr/handle/201004/126478 The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide an important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs. (C) 2014 Elsevier B.V. All rights reserved. English ELSEVIER SCIENCE BV PEGYLATED-LIPOSOMAL DOXORUBICIN ALBUMIN-BOUND PACLITAXEL GROWTH-FACTOR RECEPTOR HUMAN TUMOR XENOGRAFT RANDOMIZED PHASE-III IN-VIVO TRASTUZUMAB EMTANSINE GOLD NANOPARTICLES MACROMOLECULAR THERAPEUTICS VASCULAR-PERMEABILITY State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines Article 10.1016/j.jconrel.2014.05.036 1 JOURNAL OF CONTROLLED RELEASE, v.187, pp.133 - 144 JOURNAL OF CONTROLLED RELEASE 187 133 144 scie scopus 000338708800014 2-s2.0-84902136468 Chemistry, Multidisciplinary Pharmacology & Pharmacy Chemistry Pharmacology & Pharmacy Review PEGYLATED-LIPOSOMAL DOXORUBICIN ALBUMIN-BOUND PACLITAXEL GROWTH-FACTOR RECEPTOR HUMAN TUMOR XENOGRAFT RANDOMIZED PHASE-III IN-VIVO TRASTUZUMAB EMTANSINE GOLD NANOPARTICLES MACROMOLECULAR THERAPEUTICS VASCULAR-PERMEABILITY Tumor targeting Active targeting Nanoparticles Liposomes Circulation Enhanced permeability and retention (EPR) effect